Bottom line
How much do RXL and JDOC overlap?
51% of their top holdings overlap by weight. 12 securities appear in both funds' top 25, making up 48.9% of RXL's assets and 50.7% of JDOC's. They share a meaningful core but differ in the rest of the portfolio.
Updated Nov 22, 2026
Overlap at a glance
Holdings RXL and JDOC have in common
| Holding | % of RXL | % of JDOC | Overlap |
|---|---|---|---|
| Eli Lilly & Co. | 12.67% | 7.76% | 7.76% |
| Johnson & Johnson | 7.86% | 4.82% | 4.82% |
| AbbVie, Inc. | 5.57% | 7.85% | 5.57% |
| UnitedHealth Group, Inc. | 4.98% | 5.85% | 4.98% |
| Merck & Co., Inc. | 4.26% | 4.82% | 4.26% |
| Thermo Fisher Scientific, Inc. | 2.68% | 3.73% | 2.68% |
| Intuitive Surgical, Inc. | 2.18% | 1.93% | 1.93% |
| Abbott Laboratories | 2.15% | 3.11% | 2.15% |
| Bristol-Myers Squibb Co. | 1.68% | 3.57% | 1.68% |
| CVS Health Corp. | 1.67% | 2.83% | 1.67% |
| Danaher Corp. | 1.66% | 2.16% | 1.66% |
| Stryker Corp. | 1.52% | 2.23% | 1.52% |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in RXL
- ProShares GENIUS Money Market ETF — 11.81%
- Repurchase Agreement — 2.91%
- Amgen, Inc. — 2.62%
- Gilead Sciences, Inc. — 2.41%
- Pfizer, Inc. — 2.15%
- Repurchase Agreement — 1.83%
- Vertex Pharmaceuticals, Inc. — 1.64%
- Repurchase Agreement — 1.37%
- Medtronic plc — 1.37%
- McKesson Corp. — 1.32%
- Elevance Health, Inc. — 1.26%
- Cigna Group (The) — 1.06%
- Boston Scientific Corp. — 1.04%
Only in JDOC
- AstraZeneca plc — 3.76%
- Roche Holding AG — 2.82%
- Novo Nordisk A/S — 2.61%
- GSK plc — 2.47%
- Cencora, Inc. — 2.07%
- Argenx SE — 2.06%
- Edwards Lifesciences Corp. — 1.73%
- IQVIA Holdings, Inc. — 1.71%
- Teva Pharmaceutical Industries Ltd. — 1.60%
- Regeneron Pharmaceuticals, Inc. — 1.60%
- Novartis AG — 1.60%
- Biogen, Inc. — 1.56%
- Cardinal Health, Inc. — 1.51%
Asset mix
| Asset type | RXL | JDOC |
|---|---|---|
| Stocks | 78.0% | 99.2% |
| Other | 11.8% | — |
| Repurchase agreements | 7.1% | — |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Country mix
| Country | RXL | JDOC |
|---|---|---|
| US | 85.6% | 75.2% |
| GB | — | 6.2% |
| CH | — | 4.4% |
| DK | — | 4.0% |
| JP | — | 2.5% |
| NL | — | 2.4% |
| DE | — | 1.9% |
| IE | 1.7% | 0.4% |
Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)
Check another pair
FAQ
How much do RXL and JDOC overlap?
What stocks do RXL and JDOC have in common?
Should I own both RXL and JDOC?
Which holds more stocks, RXL or JDOC?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.